Camptothecin derivative FL118 - low toxicity anticancer agent

release time:2017年07月19日 source:This site

Camptothecin derivative FL118 - low toxicity anticancer agent

About  FL118 In 2004, the Roswell Park Cancer Institute (RPCI), LING X et al.,  Was reported (see Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, et al. A  Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1,  XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor  Activity. PLoS ONE, 2012, 7 (9): e45571. Doi: 10.1371 /  journal.pone.0045571 ). In the United  States, about 500,000 people die each year from cancer, cancer patients  are often because cancer has been resistant to the existing treatment  and eventually died. However, Scientists at the  Roswell Parker Cancer Institute (RPCI) have made breakthroughs in  overcoming cancer tolerance in 2012, and new research confirms a new  anti-cancer drug, the FL118 ) Can inhibit several genes that are closely related to the survival and reproduction of cancer cells.

Back to News Center
【神彩争霸8(广州)科技有限公司】-官网